i3 Health recently hosted Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer (TNBC): Case Explorations and Answers to FAQs, an accredited CME/NCPD webinar now available on the i3 Health website. In this video interview, Dr. Tolaney shares a preview of the important topics discussed in the activity, including approaches to treatment selection, the emerging role of novel therapies, timely management of adverse events, and much more. Oncology Data Advisor:...

i3 Health is honored to be awarded 4 years of Joint Accreditation for Interprofessional Continuing Education™ (IPCE) as a provider of continuing education for the interprofessional team by the governing bodies of the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center's Accreditation Program (ANCC). i3 Health is pleased to be among the organizations in the United States and throughou...

i3 Health is honored to be recognized as a 2022 recipient of the Nursing Continuing Professional Development (NCPD) Premier Award presented by the American Nurses Credentialing Center (ANCC) NCPD Accreditation Program. Awarded annually, the NCPD Premier Award is presented to accredited providers that excel in developing high-quality NCPD-accredited educational activities. Recipients of this prestigious award are exemplary organizations that serve as role models in the field of nursing education....

i3 Health has provided an educational activity that has challenged knowledge gaps experienced by nursing staff regarding updated treatment options and optimal patient care for immune thrombocytopenia (ITP). ITP is an autoimmune platelet disorder in which the blood does not clot normally as a result of a low platelet count, causing bruising and bleeding. Research has shown that the burden of ITP is significant; in a survey of more than 1,300 patients from 13 different countries, 36% reported a hi...

An educational live and enduring activity provided by i3 Health has demonstrated knowledge gains and learning outcomes for nurses treating patients with castration-resistant prostate cancer (CRPC). Prostate cancer is the most common tumor type in men, affecting one in eight men in the United States. The estimate for 2022 is expecting 268,490 new cases of prostate cancer, with 34,500 of those cases resulting in death. The typical treatment for progressive prostate disease is androgen deprivation ...

i3 Health's study focusing on the effectiveness of a nursing continuing professional development (NCPD)–approved activity to improve clinicians' knowledge of the individualized treatment of patients with non-Hodgkin lymphoma (NHL) has been published as a 47th Annual Oncology Nursing Society (ONS) Congress online abstract. The abstract, authored by Elizabeth Heller, PhD; Keira Smith, BA; Kristin Wright, PharmD; and Sarah Williams, MAT, of i3 Health, and Maria Badillo, MSN, RN, OCN®, CCRP, Researc...

i3 Health would like to cordially invite you to our upcoming event, Diagnosis and Evidence-Based Management of T-Cell Lymphoma, a live CME/NCPD-approved webinar. Due to high demand, we are pleased to offer two dates and times for this expert-led discussion: Monday, June 13, 2022, at 3:00 PM EDT, and Friday, June 17, 2022, at 12:00 PM EDT. T-cell lymphoma (TCL) is an uncommon subtype accounting for approximately 15% of all cases of non-Hodgkin lymphoma in the United States. The clinical and patho...

An educational live and enduring activity provided by i3 Health has demonstrated significant learning outcomes for treatment of patients with advanced non-Hodgkin lymphoma (NHL). The live activity, which was presented virtually at the 4th Annual GLAONS Oncology Care Summit, used a competitive, team-based "game show" format to explore the latest strategies and expert perspectives in treatment of patients with advanced NHL, including subtypes of follicular lymphoma (FL) and chronic lymphocytic leu...

Multiple myeloma is a cancer of the bone marrow plasma cells that causes the overproduction of monoclonal immunoglobulins, which can lead to organ damage. In this excerpt of the transcript from her nursing continuing professional development (NCPD)-approved activity, Multiple Myeloma: Enhancing Treatment Tolerability, Adherence, and Patient-Centered Care, Beth Faiman, PhD, MSN, APN-BC, AOCN®, FAAN, a nurse practitioner at the Cleveland Clinic Taussig Cancer Institute, discusses strateg...

Myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocytopenia, affect approximately 13,000, 134,000, and 148,000 individuals in the United States, respectively. Due to difficulties in identifying the disease, low disease prevalence, a complicated symptom profile, differences in patient and provider perspectives regarding symptom burden and treatment goals, and a lack of effective and tolerable therapies, there is confusion over the optimal approach to t...